Sequist LV - Search Results

1

Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.

Mak RH, Doran E, Muzikansky A, Kang J, Neal JW, Baldini EH, Choi NC, Willers H, Jackman DM, Sequist LV. Mak RH, et al. Among authors: sequist lv. Oncologist. 2011;16(6):886-95. doi: 10.1634/theoncologist.2011-0040. Epub 2011 May 31. Oncologist. 2011. PMID: 21632451 Free PMC article.

2

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA. Jackman DM, et al. Among authors: sequist lv. Clin Cancer Res. 2006 Jul 1;12(13):3908-14. doi: 10.1158/1078-0432.CCR-06-0462. Clin Cancer Res. 2006. PMID: 16818686

3

Epidermal growth factor receptor mutation testing in the care of lung cancer patients.

Sequist LV, Joshi VA, Jänne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ. Sequist LV, et al. Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4403s-4408s. doi: 10.1158/1078-0432.CCR-06-0099. Clin Cancer Res. 2006. PMID: 16857818 Review.

4

Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.

Sequist LV, Joshi VA, Jänne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJ. Sequist LV, et al. Oncologist. 2007 Jan;12(1):90-8. doi: 10.1634/theoncologist.12-1-90. Oncologist. 2007. PMID: 17285735 Free article.

5

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.

Sequist LV, Bell DW, Lynch TJ, Haber DA. Sequist LV, et al. J Clin Oncol. 2007 Feb 10;25(5):587-95. doi: 10.1200/JCO.2006.07.3585. J Clin Oncol. 2007. PMID: 17290067 Review.

6

Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.

Sequist LV. Sequist LV. Oncologist. 2007 Mar;12(3):325-30. doi: 10.1634/theoncologist.12-3-325. Oncologist. 2007. PMID: 17405897 Free article. Review.

7

Update on epidermal growth factor receptor inhibitor development in lung cancer.

Sequist LV, Dziadziuszko R. Sequist LV, et al. J Thorac Oncol. 2006 Sep;1(7):740-3. J Thorac Oncol. 2006. PMID: 17409951 Free article.

8

Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features.

Finberg KE, Sequist LV, Joshi VA, Muzikansky A, Miller JM, Han M, Beheshti J, Chirieac LR, Mark EJ, Iafrate AJ. Finberg KE, et al. Among authors: sequist lv. J Mol Diagn. 2007 Jul;9(3):320-6. doi: 10.2353/jmoldx.2007.060182. J Mol Diagn. 2007. PMID: 17591931 Free PMC article.

9

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.

Sequist LV, Lynch TJ. Sequist LV, et al. Annu Rev Med. 2008;59:429-42. doi: 10.1146/annurev.med.59.090506.202405. Annu Rev Med. 2008. PMID: 17716025 Review.

10

Non-small cell lung cancer in octogenarians: treatment practices and preferences.

Oxnard GR, Fidias P, Muzikansky A, Sequist LV. Oxnard GR, et al. Among authors: sequist lv. J Thorac Oncol. 2007 Nov;2(11):1029-35. doi: 10.1097/JTO.0b013e318158d4a2. J Thorac Oncol. 2007. PMID: 17975495 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

289 results

Search Page

Filters